Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about us:
Ascelia Pharma Company Introduction – October 2024
TOP STORIES
Ascelia Pharma Announces Final Outcome in Fully Subscribed SEK 105 Million Rights Issue
2024-09-06
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, [ …
TOP STORIES
Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study
2024-05-02 11:12:00
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance®, signif …
TOP STORIES
Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024
2024-04-08 17:45:00
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Ascelia Pharma AB (publ) (ticker: [&he …
Upcoming Events
Latest News
Presentations & Articles
INVESTOR
Shortcut to our latest Financial Reports
Key downloads
Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 StudyQuarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 StudyAnnual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in MayQUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan